Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
Quarterly revenue exceeds
-
4Q21 total company net revenue is expected to be in the range of
$52.9 to$53.3 million , an increase of 53% compared to$34.8 million in the prior year period.-
4Q21 sacral neuromodulation (SNM) net revenue is expected to be in the range of
$44.2 to$44.4 million , an increase of 27% compared to$34.8 million in the prior year period. -
4Q21 Bulkamid® net revenue is expected to be in the range of
$8.7 to$8.9 million .
-
4Q21 sacral neuromodulation (SNM) net revenue is expected to be in the range of
-
Fiscal year 2021 total company net revenue is expected to be in the range of
$180.1 to$180.5 million , an increase of 62% compared to$111.5 million in fiscal year 2020.-
Fiscal year 2021 sacral neuromodulation net revenue is expected to be in the range of
$157.4 to$157.6 million , an increase of 41% compared to$111.5 million in fiscal year 2020. -
Fiscal year 2021 Bulkamid net revenue is expected to be in the range of
$22.7 to$22.9 million . (1)
-
Fiscal year 2021 sacral neuromodulation net revenue is expected to be in the range of
___________
(1) The acquisition of Bulkamid was completed on
“We are very proud of this quarter and fiscal year's results considering the disruption Covid-19 has had on elective procedures in health care facilities in the
Cohen continued, “In 2022, we expect the introduction of our long-lived, recharge-free SNM system in the first half of 2022 to set a new standard for what is possible in this category. We are also eagerly looking forward to launching a national television direct-to-consumer advertising campaign as we continue to increase awareness for
The preliminary results are unaudited and remain subject to adjustment.
About
Based in
The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the
Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005321/en/
Investor Relations
949-336-5293
ir@axonics.com
Source: